Income StatementBalance SheetCash FlowSegments
Edwards Lifesciences logo

Edwards Lifesciences Cash Flow Statement

Operating, investing, and financing cash movements

Edwards Lifesciences generated $1.4B in operating cash flow over the trailing twelve months. After $269.1M in capital expenditures, free cash flow was $1.1B. Free cash flow increased 0.6% year-over-year. Based on the Q1 2026 filing.

Net Cash From Operating (TTM)$1.4BNet Cash From Investing (TTM)-$891.0MNet Cash From Financing (TTM)-$1.2BCapital Expenditures (TTM)$269.1MDepreciation And Amortization Cf (TTM)$160.9MNet Change In Cash (TTM)$162.2M
Latest FilingQ1 2026
Report Date2026-05-06
Market Cap$46.9B
P/E Ratio42.75
ROE10.72%

Investing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Payments to acquire interest in subsidiaries and affiliates$15.1M$0.0$48.3M$1.5M$15.0M$6.3M
Capital expenditures$49.8M$56.0M$49.3M$57.5M$97.4M$64.9M
Other Payments to Acquire Businesses$30.0M$3.0M$14.0M$2.6M$5.5M$0.0
Payment for (Proceeds from) Other Investing Activity$36.5M-$100.0K$3.5M$4.5M$0.0$300.0K
Payments to Acquire Held-to-Maturity Securities$9.6M$12.8M$6.0M$24.4M$100.0K$12.5M
Payments to Acquire Receivables$35.0M$17.8M$52.8M$22.8M$47.5M$55.2M
Proceeds From Sale And Maturity Of Available For Sale Securities$261.0M$827.9M$611.8M$669.7M$706.6M$710.1M
Net cash from investing activities—$85.3M-$172.1M-$427.8M-$198.3M-$92.8M
Purchases of investments$381.1M$634.5M$624.3M$1.0B$826.6M$641.1M
Proceeds from Sale and Maturity of Held-to-Maturity Securities$7.1M$17.7M$14.3M$22.2M$7.9M$12.5M

Operating

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Change in accounts payable$0.0-$103.4M$103.7M$226.1M$168.7M-$347.1M
Change in income taxes payable/receivable-$488.5M$51.2M-$240.4M-$10.2M—$41.9M
Change in inventories$51.2M$100.0K-$41.6M$1.8M-$11.0M$1.6M
Other working capital changes$11.1M$28.6M-$4.7M$7.9M$2.7M$18.1M
Depreciation and amortization$42.6M$36.6M$38.1M$39.2M$42.7M$40.9M
Net cash from operating activities—$280.4M$290.2M$573.7M$450.9M$43.8M
Net income$384.3M$356.4M$331.5M$290.3M$91.2M$380.7M
Asset write-downs—$0.0$47.1M——$123.6M
Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain Or Loss$13.8M$0.0———$65.2M
Gain (Loss) on Investments—-$12.5M———-$3.5M
Increase (Decrease) in Accounts and Other Receivables-$105.9M$43.7M$24.9M-$13.2M—$117.9M
Increase (Decrease) in Deferred Income Taxes$98.5M$24.3M$20.9M$18.0M$54.4M-$9.4M
Intellectual property agreement accrual-$12.5M-$36.7M-$12.5M-$12.5M-$14.8M-$50.0M
Increase (Decrease) in Prepaid Expense and Other Assets—-$10.6M$13.9M$14.2M$6.2M$8.7M
Operating lease right-of-use asset amortization$6.2M$6.1M$6.4M$6.8M$6.6M$6.5M
Other Noncash Income (Expense)-$15.7M-$3.6M-$4.7M$6.0M-$5.4M-$500.0K
Stock-based compensation$31.7M$40.2M$37.5M$41.2M$39.2M$45.4M

Financing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Other, net$0.0$700.0K$1.0M-$2.4M-$3.1M$1.7M
Proceeds from issuance of common stock relating to employee stock plans$28.6M$49.9M$57.2M$34.7M$32.3M$68.9M
Net cash from financing activities$0.0-$258.0M$52.7M-$740.1M-$11.4M-$451.2M
Repurchases of common stock$100.1M$258.6M$5.5M$588.7M$40.6M$421.8M

Free Cash Flow

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Free cash flow—$224.4M$240.9M$516.2M$353.5M-$21.1M

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Effect of exchange rate changes on cash$51.0M-$17.7M-$29.6M-$1.0M$0.0$8.2M
Net increase (decrease) in cash—$90.0M$141.2M-$595.2M—-$492.0M
Payment for working capital adjustment for sale of product group$0.0$36.3M$0.0$0.0$0.0$0.0
Payments For Equity Forward Contract Related To Accelerated Share Repurchase Agreement—$50.0M$0.0-$50.0M—$100.0M
Payments To Acquire Businesses, Net Of Cash Acquired, Excluding Options$298.2M$0.0———$35.1M